Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
Identifieur interne : 001C24 ( Main/Exploration ); précédent : 001C23; suivant : 001C25Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
Auteurs : Cem Gabay [Suisse] ; Iain B. Mcinnes [Royaume-Uni] ; Arthur Kavanaugh [États-Unis] ; Katie Tuckwell [Royaume-Uni] ; Micki Klearman [États-Unis] ; Jennifer Pulley [Royaume-Uni] ; Naveed Sattar [Royaume-Uni]Source :
- Annals of the rheumatic diseases [ 1468-2060 ] ; 2016.
Descripteurs français
- KwdFr :
- Adalimumab (administration et posologie), Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (administration et posologie), Antirhumatismaux (administration et posologie), Facteurs de risque, Femelle, Humains, Lipides (sang), Lipoprotéine (a) (sang), Lipoprotéines HDL (sang), Maladies cardiovasculaires (étiologie), Marqueurs biologiques (sang), Mâle, Polyarthrite rhumatoïde (), Polyarthrite rhumatoïde (sang), Polyarthrite rhumatoïde (traitement médicamenteux), Protéine amyloïde A sérique (analyse), Résultat thérapeutique, Secretory Phospholipases A2 (sang).
- MESH :
- administration et posologie : Adalimumab, Anticorps monoclonaux humanisés, Antirhumatismaux.
- analyse : Protéine amyloïde A sérique.
- sang : Lipides, Lipoprotéine (a), Lipoprotéines HDL, Marqueurs biologiques, Polyarthrite rhumatoïde, Secretory Phospholipases A2.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- étiologie : Maladies cardiovasculaires.
- Adulte, Adulte d'âge moyen, Facteurs de risque, Femelle, Humains, Mâle, Polyarthrite rhumatoïde, Résultat thérapeutique.
English descriptors
- KwdEn :
- Adalimumab (administration & dosage), Adult, Antibodies, Monoclonal, Humanized (administration & dosage), Antirheumatic Agents (administration & dosage), Arthritis, Rheumatoid (blood), Arthritis, Rheumatoid (complications), Arthritis, Rheumatoid (drug therapy), Biomarkers (blood), Cardiovascular Diseases (etiology), Female, Humans, Lipids (blood), Lipoprotein(a) (blood), Lipoproteins, HDL (blood), Male, Middle Aged, Phospholipases A2, Secretory (blood), Risk Factors, Serum Amyloid A Protein (analysis), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Adalimumab, Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- chemical , analysis : Serum Amyloid A Protein.
- blood : Arthritis, Rheumatoid, Biomarkers, Lipids, Lipoprotein(a), Lipoproteins, HDL, Phospholipases A2, Secretory.
- complications : Arthritis, Rheumatoid.
- drug therapy : Arthritis, Rheumatoid.
- etiology : Cardiovascular Diseases.
- Adult, Female, Humans, Male, Middle Aged, Risk Factors, Treatment Outcome.
Abstract
Compare changes in lipids and lipid-associated cardiovascular (CV) risk markers in patients with rheumatoid arthritis (RA) treated with tocilizumab or adalimumab.
DOI: 10.1136/annrheumdis-2015-207872
PubMed: 26613768
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001006
- to stream PubMed, to step Curation: 001006
- to stream PubMed, to step Checkpoint: 000E95
- to stream Ncbi, to step Merge: 001000
- to stream Ncbi, to step Curation: 001000
- to stream Ncbi, to step Checkpoint: 001000
- to stream Main, to step Merge: 001C24
- to stream Main, to step Curation: 001C24
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.</title><author><name sortKey="Gabay, Cem" sort="Gabay, Cem" uniqKey="Gabay C" first="Cem" last="Gabay">Cem Gabay</name><affiliation wicri:level="1"><nlm:affiliation>University Hospitals, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University Hospitals, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Mcinnes, Iain B" sort="Mcinnes, Iain B" uniqKey="Mcinnes I" first="Iain B" last="Mcinnes">Iain B. Mcinnes</name><affiliation wicri:level="4"><nlm:affiliation>University of Glasgow, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Kavanaugh, Arthur" sort="Kavanaugh, Arthur" uniqKey="Kavanaugh A" first="Arthur" last="Kavanaugh">Arthur Kavanaugh</name><affiliation wicri:level="2"><nlm:affiliation>University of California, San Diego, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of California, San Diego, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Tuckwell, Katie" sort="Tuckwell, Katie" uniqKey="Tuckwell K" first="Katie" last="Tuckwell">Katie Tuckwell</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd, Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd, Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Klearman, Micki" sort="Klearman, Micki" uniqKey="Klearman M" first="Micki" last="Klearman">Micki Klearman</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Pulley, Jennifer" sort="Pulley, Jennifer" uniqKey="Pulley J" first="Jennifer" last="Pulley">Jennifer Pulley</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd, Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd, Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Sattar, Naveed" sort="Sattar, Naveed" uniqKey="Sattar N" first="Naveed" last="Sattar">Naveed Sattar</name><affiliation wicri:level="4"><nlm:affiliation>University of Glasgow, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26613768</idno><idno type="pmid">26613768</idno><idno type="doi">10.1136/annrheumdis-2015-207872</idno><idno type="wicri:Area/PubMed/Corpus">001006</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001006</idno><idno type="wicri:Area/PubMed/Curation">001006</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001006</idno><idno type="wicri:Area/PubMed/Checkpoint">000E95</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E95</idno><idno type="wicri:Area/Ncbi/Merge">001000</idno><idno type="wicri:Area/Ncbi/Curation">001000</idno><idno type="wicri:Area/Ncbi/Checkpoint">001000</idno><idno type="wicri:Area/Main/Merge">001C24</idno><idno type="wicri:Area/Main/Curation">001C24</idno><idno type="wicri:Area/Main/Exploration">001C24</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.</title><author><name sortKey="Gabay, Cem" sort="Gabay, Cem" uniqKey="Gabay C" first="Cem" last="Gabay">Cem Gabay</name><affiliation wicri:level="1"><nlm:affiliation>University Hospitals, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University Hospitals, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Mcinnes, Iain B" sort="Mcinnes, Iain B" uniqKey="Mcinnes I" first="Iain B" last="Mcinnes">Iain B. Mcinnes</name><affiliation wicri:level="4"><nlm:affiliation>University of Glasgow, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Kavanaugh, Arthur" sort="Kavanaugh, Arthur" uniqKey="Kavanaugh A" first="Arthur" last="Kavanaugh">Arthur Kavanaugh</name><affiliation wicri:level="2"><nlm:affiliation>University of California, San Diego, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of California, San Diego, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Tuckwell, Katie" sort="Tuckwell, Katie" uniqKey="Tuckwell K" first="Katie" last="Tuckwell">Katie Tuckwell</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd, Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd, Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Klearman, Micki" sort="Klearman, Micki" uniqKey="Klearman M" first="Micki" last="Klearman">Micki Klearman</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Pulley, Jennifer" sort="Pulley, Jennifer" uniqKey="Pulley J" first="Jennifer" last="Pulley">Jennifer Pulley</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd, Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd, Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Sattar, Naveed" sort="Sattar, Naveed" uniqKey="Sattar N" first="Naveed" last="Sattar">Naveed Sattar</name><affiliation wicri:level="4"><nlm:affiliation>University of Glasgow, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author></analytic><series><title level="j">Annals of the rheumatic diseases</title><idno type="eISSN">1468-2060</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adalimumab (administration & dosage)</term><term>Adult</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antirheumatic Agents (administration & dosage)</term><term>Arthritis, Rheumatoid (blood)</term><term>Arthritis, Rheumatoid (complications)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Biomarkers (blood)</term><term>Cardiovascular Diseases (etiology)</term><term>Female</term><term>Humans</term><term>Lipids (blood)</term><term>Lipoprotein(a) (blood)</term><term>Lipoproteins, HDL (blood)</term><term>Male</term><term>Middle Aged</term><term>Phospholipases A2, Secretory (blood)</term><term>Risk Factors</term><term>Serum Amyloid A Protein (analysis)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adalimumab (administration et posologie)</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Antirhumatismaux (administration et posologie)</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Lipides (sang)</term><term>Lipoprotéine (a) (sang)</term><term>Lipoprotéines HDL (sang)</term><term>Maladies cardiovasculaires (étiologie)</term><term>Marqueurs biologiques (sang)</term><term>Mâle</term><term>Polyarthrite rhumatoïde ()</term><term>Polyarthrite rhumatoïde (sang)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Protéine amyloïde A sérique (analyse)</term><term>Résultat thérapeutique</term><term>Secretory Phospholipases A2 (sang)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adalimumab</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Serum Amyloid A Protein</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adalimumab</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Protéine amyloïde A sérique</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Biomarkers</term><term>Lipids</term><term>Lipoprotein(a)</term><term>Lipoproteins, HDL</term><term>Phospholipases A2, Secretory</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Lipides</term><term>Lipoprotéine (a)</term><term>Lipoprotéines HDL</term><term>Marqueurs biologiques</term><term>Polyarthrite rhumatoïde</term><term>Secretory Phospholipases A2</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Maladies cardiovasculaires</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Polyarthrite rhumatoïde</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Compare changes in lipids and lipid-associated cardiovascular (CV) risk markers in patients with rheumatoid arthritis (RA) treated with tocilizumab or adalimumab.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Californie</li><li>Écosse</li></region><settlement><li>Glasgow</li></settlement><orgName><li>Université de Glasgow</li></orgName></list><tree><country name="Suisse"><noRegion><name sortKey="Gabay, Cem" sort="Gabay, Cem" uniqKey="Gabay C" first="Cem" last="Gabay">Cem Gabay</name></noRegion></country><country name="Royaume-Uni"><region name="Écosse"><name sortKey="Mcinnes, Iain B" sort="Mcinnes, Iain B" uniqKey="Mcinnes I" first="Iain B" last="Mcinnes">Iain B. Mcinnes</name></region><name sortKey="Pulley, Jennifer" sort="Pulley, Jennifer" uniqKey="Pulley J" first="Jennifer" last="Pulley">Jennifer Pulley</name><name sortKey="Sattar, Naveed" sort="Sattar, Naveed" uniqKey="Sattar N" first="Naveed" last="Sattar">Naveed Sattar</name><name sortKey="Tuckwell, Katie" sort="Tuckwell, Katie" uniqKey="Tuckwell K" first="Katie" last="Tuckwell">Katie Tuckwell</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Kavanaugh, Arthur" sort="Kavanaugh, Arthur" uniqKey="Kavanaugh A" first="Arthur" last="Kavanaugh">Arthur Kavanaugh</name></region><name sortKey="Klearman, Micki" sort="Klearman, Micki" uniqKey="Klearman M" first="Micki" last="Klearman">Micki Klearman</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26613768
|texte= Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26613768" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |